175 related articles for article (PubMed ID: 7688829)
21. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
22. [Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].
Aso Y; Akaza H; Koiso K; Kumamoto Y; Kawai T; Origasa S; Hosaka M; Yamanaka H; Shimazaki J; Fuse H
Hinyokika Kiyo; 1993 Apr; 39(4):381-9. PubMed ID: 8503338
[TBL] [Abstract][Full Text] [Related]
23. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
[TBL] [Abstract][Full Text] [Related]
24. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
26. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
28. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
[TBL] [Abstract][Full Text] [Related]
29. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
Fleshner NE; Trachtenberg J
J Urol; 1995 Nov; 154(5):1642-5; discussion 1645-6. PubMed ID: 7563310
[TBL] [Abstract][Full Text] [Related]
30. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
Akakura K; Akimoto S; Ohki T; Shimazaki J
Urology; 1995 Apr; 45(4):700-4; discussion 704-5. PubMed ID: 7536369
[TBL] [Abstract][Full Text] [Related]
31. A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer.
Ozono S; Okajima E; Yamaguchi A; Yoshikawa M; Iwai A; Moriya A; Yoshida K; Samma S; Maruyama Y; Hirao Y
Jpn J Clin Oncol; 2000 Sep; 30(9):389-96. PubMed ID: 11095136
[TBL] [Abstract][Full Text] [Related]
32. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
33. Local injection of a sustained-release antiandrogen formulation into a target prostatic site: an experimental study.
Goya N; Gotanda K; Sasaki T; Okada M; Tomizawa Y; Toma H
BJU Int; 2007 Jan; 99(1):202-6. PubMed ID: 17092292
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Boccardo F; Rubagotti A; Battaglia M; Di Tonno P; Selvaggi FP; Conti G; Comeri G; Bertaccini A; Martorana G; Galassi P; Zattoni F; Macchiarella A; Siragusa A; Muscas G; Durand F; Potenzoni D; Manganelli A; Ferraris V; Montefiore F
J Clin Oncol; 2005 Feb; 23(4):808-15. PubMed ID: 15681525
[TBL] [Abstract][Full Text] [Related]
36. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
37. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
38. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
40. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
